pancreatic cancer (HLA type A2/A24)
Conditions
Interventions
Radiation therapy Gemcitabine Alpha-Beta T-cell Therapy
Sponsors
Gunma University
Seta Clinic Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Patient with locally advanced pancreatic cancer without prior treatment (2)Patient who can be treated with adoptive immune-cell therapy and chemoradiotherapy (3)Patient with HLA A2 and/or A24 (4)Patient age of 20 to 80 years (5)Patient with performance status 0-2 (6)Patient has more than three months of expected life time (7)Patient with no serious abnormality in bone marrow, liver, and renal functions (8)Patient agrees to participate in this study with informed consent
Exclusion criteria
Exclusion criteria: (1)Patient with interstitial pneumonia (2)Patient with active autoimmune disease (3)Patient with active heart disease (4)Patient with uncontrolable infectious diseases (5)Patient with serious drug allergy (6)Patient with continuous use of systemic administration of steroids (7)Patient in pregnancy (8)Patient positive for HIV or HTLV-1 (9)patient who is inadequate to enter this study due to the other reasons by physician's judgments
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease-free rate | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival period overall survival rate Distant metastasis-free survival rete Frequency and type of adverse events QOL immunological parameters | — |
Countries
Japan
Contacts
Public ContactYoshiyuki Suzuki
Gunma University Department of Radiation Oncology, Gunma University Graduate School of Medicine
Outcome results
None listed